Next-gen Novo Nordisk shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...
Hosted on MSN3m
Is Novo Nordisk (NVO) the Best Falling Stock to Invest in Right Now?
We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...
Novo Nordisk Shares Surge on New Obesity Drug Results — Update
The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...
STAT36m
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
Investing29m
Eli Lilly stock dips on Novo Nordisk's rival drug data
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
ENDPOINTS NEWS57m
No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al
Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...